Opendata, web and dolomites

ADJUV-ANT VACCINES SIGNED

Elucidating the Molecular Mechanisms of Synthetic Saponin Adjuvants and Development of Novel Self-Adjuvanting Vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADJUV-ANT VACCINES project word cloud

Explore the words cloud of the ADJUV-ANT VACCINES project. It provides you a very rough idea of what is the project "ADJUV-ANT VACCINES" about.

structure    conformational    dimensional    helps    integration    cancer    extensive    group    ground    glycopeptide    stems    chemical    cellular    immunological    self    me    efficacy    fight    trials    ultimate    chemistry    biological    clinic    extraordinary    weak    mechanisms    substance    few    multidisciplinary    synthetic    constructs    insights    biology    deeply    double    mechanistic    precision    really    connecting    strategies    despite    vaccines    unresolved    prospective    adjuvanting    antiviral    breaking    basis    vaccine    antitumor    questions    adjuvants    anticancer    transformative    clear    carbohydrate    clinical    public    intensive    identification    sufficiently    potent    immune    singularity    probe    arena    context    immunology    adjuvant    explore    first    antigens    induce    mount    translation    approved    frontier    evaluations    independent    human    synthesis    gain    toxic    stimulate    combining    gaps    underlying    critical    molecular    body    structural   

Project "ADJUV-ANT VACCINES" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.cicbiogune.es/people/afernandeztejada
 Total cost 1˙499˙218 €
 EC max contribution 1˙499˙218 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 1˙499˙218.00

Map

 Project objective

The clinical success of anticancer and antiviral vaccines often requires the use of an adjuvant, a substance that helps stimulate the body’s immune response to the vaccine, making it work better. However, few adjuvants are sufficiently potent and non-toxic for clinical use; moreover, it is not really known how they work. Current vaccine approaches based on weak carbohydrate and glycopeptide antigens are not being particularly effective to induce the human immune system to mount an effective fight against cancer. Despite intensive research and several clinical trials, no such carbohydrate-based antitumor vaccine has yet been approved for public use. In this context, the proposed project has a double, ultimate goal based on applying chemistry to address the above clear gaps in the adjuvant-vaccine field. First, I will develop new improved adjuvants and novel chemical strategies towards more effective, self-adjuvanting synthetic vaccines. Second, I will probe deeply into the molecular mechanisms of the synthetic constructs by combining extensive immunological evaluations with molecular target identification and detailed conformational studies. Thus, the singularity of this multidisciplinary proposal stems from the integration of its main objectives and approaches connecting chemical synthesis and chemical/structural biology with cellular and molecular immunology. This ground-breaking project at the chemistry-biology frontier will allow me to establish my own independent research group and explore key unresolved mechanistic questions in the adjuvant/vaccine arena with extraordinary chemical precision. Therefore, with this transformative and timely research program I aim to (a) develop novel synthetic antitumor and antiviral vaccines with improved properties and efficacy for their prospective translation into the clinic and (b) gain new critical insights into the molecular basis and three-dimensional structure underlying the biological activity of these constructs.

 Publications

year authors and title journal last update
List of publications.
2020 Mattia Ghirardello, Ane Ruiz-de-Angulo, Nagore Sacristan, Diego Barriales, Jesús Jiménez-Barbero, Ana Poveda, Francisco Corzana, Juan Anguita, Alberto Fernández-Tejada
Exploiting structure–activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants
published pages: 719-722, ISSN: 1359-7345, DOI: 10.1039/c9cc07781b
Chemical Communications 56/5 2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADJUV-ANT VACCINES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADJUV-ANT VACCINES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

CUSTOMER (2019)

Customizable Embedded Real-Time Systems: Challenges and Key Techniques

Read More  

CARBYNE (2020)

New carbon reactivity rules for molecular editing

Read More